Rebecca McWhirter, NP
Adult Health · Ridgeland, MSNPI 1902421746
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 183 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $880, more than ten times the $60 reported in 2021.
Across 183 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$484
- Novo Nordisk$428
- AbbVie$388
- Amgen$359
- GSK$266
- Lilly USA, LLC$176
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,20198%
- Other$532%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 28 | $484 |
| Novo Nordisk | 22 | $428 |
| AbbVie | 25 | $388 |
| Amgen | 18 | $359 |
| GSK | 14 | $266 |
| Lilly USA, LLC | 12 | $176 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $132 |
| Novartis | 6 | $111 |
| Acadia Pharmaceuticals Inc | 4 | $102 |
| Merck | 5 | $92 |
| Sunovion Pharmaceuticals Inc. | 6 | $85 |
| AstraZeneca | 5 | $79 |
| Exact Sciences | 4 | $62 |
| Sumitomo Pharma America, Inc. | 3 | $55 |
| Welch Allyn | 1 | $53 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $53 |
| Shield Therapeutics Inc | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Medtronic | 2 | $39 |
| Seqirus USA Inc | 2 | $29 |
| Boehringer Ingelheim | 2 | $28 |
| Inari Medical, Inc. | 1 | $28 |
| Abbott | 1 | $22 |
| Edwards Lifesciences | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Genentech USA, Inc. | 1 | $7 |
How this compares
$3,253 in reported general payments places this provider in the 85th percentile of 93 adult health providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 12 | $28,700 |
| JardianceEmpagliflozin | 20 | $21,935 |
| OzempicSemaglutide | 22 | $19,565 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,565 |
| EliquisApixaban | 13 | $7,483 |
| Repatha SureclickEvolocumab | 12 | $6,296 |
| Atorvastatin Calcium | 109 | $892 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $639 |
| CefuroximeCefuroxime Axetil | 46 | $555 |
| Rosuvastatin Calcium | 83 | $555 |
| Valsartan | 37 | $548 |
| Amlodipine Besylate | 101 | $462 |
| ValacyclovirValacyclovir Hcl | 14 | $455 |
| Ezetimibe | 18 | $411 |
| Levothyroxine Sodium | 47 | $396 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $28 | $21,93520 claims |
| Novo NordiskOzempic | $428 | $19,56522 claims |
| GSKBreo Ellipta | $266 | $7,56519 claims |
| PfizerEliquis | $484 | $7,48313 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $39647 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 93 adult health providers in Mississippi.
Other adult health in Ridgeland
- Amanda GreeneRidgeland$108K
- Joshua LedfordRidgeland$3K
- Stephanie FarriorRidgeland$2K
- Michelle HughesRidgeland$444
- Rhonda HickmanTupelo$15K
- Angela SlaterFlorence$14K
- Jennifer Delaney-DavisOcean Springs$9K
- Traci EvansGulfport$8K
- Casey AdamsGulfport$8K
- Keila BrownJackson$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.